SKF 525-A inhibition of hepatic monooxygenase activity in rhesus monkeys

Area of Science:

• Pharmacology
• Toxicology
• Drug Metabolism

Background:

• Hepatic monooxygenase activity is crucial for drug metabolism and elimination.
• SKF 525-A is a known inhibitor of certain cytochrome P450 enzymes.
• Understanding drug interactions and metabolic pathways is vital in preclinical research.

Purpose of the Study:

• To investigate the effect of SKF 525-A on antipyrine pharmacokinetics in rhesus monkeys.
• To assess the impact of SKF 525-A on antipyrine metabolite levels and hepatic enzyme activity.
• To compare analytical methods for determining antipyrine plasma half-life.

Main Methods:

• Rhesus monkeys were pretreated with SKF 525-A before intravenous administration of 14C-labeled antipyrine.
• Antipyrine plasma half-life (APH) was measured over several days using both High-Performance Liquid Chromatography (HSLC) and radiometric methods.
• Plasma metabolite concentrations (3-hydroxymethylantipyrine, 4-hydroxyantipyrine) and liver homogenate aldrin epoxidation rates were determined.

Main Results:

• SKF 525-A pretreatment increased antipyrine plasma half-life by 240-500%.
• Elevated APH persisted for at least 11 days post-treatment.
• Decreased plasma levels of antipyrine metabolites and reduced aldrin epoxidation rates were observed, correlating with prolonged APH.
• Both HSLC and radiometric methods effectively detected alterations in hepatic monooxygenase activity.

Conclusions:

• SKF 525-A significantly inhibits antipyrine metabolism in rhesus monkeys, leading to prolonged drug half-life.
• The study demonstrates the utility of antipyrine as a probe substrate for assessing hepatic monooxygenase inhibition.
• Both HSLC and radiometric assays are suitable for monitoring drug metabolism changes induced by enzyme inhibitors.